FDA Form 483

Regulatory Event

FDA investigator Lisa R. Hilliard of the Maitland, Florida District Office closed a 10-day inspection of BPI Labs, LLC’s 503B outsourcing facility in Largo, Florida on April 17, 2026, documenting four observations addressing bulk drug substance compliance, media fill design, visual inspection qualification, stability testing, and equipment cleaning. The Form 483, issued to Chairman and CEO Jugal K. Taneja, is an inspectional record — not a finding that BPI Labs violated the Federal Food, Drug, and Cosmetic Act — and the firm has 15 business days to respond before FDA’s Center for Drug Evaluation and Research determines whether the response adequately addresses what investigators observed. The context matters: BPI Labs already carries a Warning Letter (699533, issued March 25, 2025, concerning an unapproved new drug) and a prior 483 (February 21, 2025, documenting 503B labeling deficiencies on semaglutide and tirzepatide vials) — meaning this is the second documented compliance matter in just over a year tied to the same GLP-1/incretin product family now under heightened, nationwide FDA compounding scrutiny.

Observation 1 documents a distinct and consequential finding: FDA investigators observed BPI Labs compounding human drug products using tirzepatide bulk drug substance, which, per the observation, does not appear on either the FDA drug shortage list maintained under Section 506E of the FD&C Act or on FDA’s list of bulk drug substances for which a clinical need has been established for 503B compounding. Section 503B permits outsourcing facilities to compound from bulk drug substances only when one of those two conditions is met; an observation stating neither condition applies is not a technical nuance — it is a foundational compounding-eligibility question that sits above the aseptic process findings that follow. Whether and how the response addresses this eligibility gap, including whether affected lots require broader assessment, will likely be the single most scrutinized element of BPI Labs’ reply.

What the Record Documents

The remaining three observations turn to the sterility assurance system itself, and observation 2, cited under 21 CFR 211.22(d), is the most substantive: media fills across three separate product lines — Liraglutide Injection 18 mg/3 mL, Testosterone Cypionate Injection 1000 mg/5 mL, and Tirzepatide and Pyridoxine Hydrochloride Injection — did not represent worst-case production conditions. FDA’s 2004 Guidance for Industry on Sterile Drug Products Produced by Aseptic Processing expects media fills to simulate the most challenging conditions a line actually runs: the largest vial count, longest fill duration, and full range of vial sizes and fill volumes used in commercial production. Here, the cited media fills used fewer vials, shorter run times, or a narrower set of vial types than the batches subsequently released — for example, a media fill using a single fill volume was offered as support for a Liraglutide batch produced at a substantially higher vial count and longer run time. A media fill that does not challenge the process at its actual production extremes provides materially weaker assurance that the line reliably excludes microbial contamination during real manufacturing.

Observation 2 also documents that automated visual inspection false-reject rates exceeded the established limit on nine occasions between January and November 2025 without triggering system revalidation, that false-reject vials were returned to the accepted population without documented Quality verification, and that extrinsic particles such as glass were classified as major defects rather than critical — a classification choice that matters because critical defects typically drive mandatory batch-disposition review, while major defects may not. Under Grade A/ISO 5 aseptic processing expectations, a visual inspection system’s reject/accept performance must be scientifically justified and periodically requalified against defined defect libraries; an unexplained false-reject rate that recurs nine times without triggering revalidation indicates the system’s detection capability is not well characterized, which undercuts confidence in every batch it has released since.

Technical and Quality Context

This combination — an active Warning Letter, a second compounding-eligibility or labeling issue within the same product family, and now media fill and visual inspection qualification gaps — is the profile FDA has increasingly escalated through import alerts or product-specific enforcement action at 503B facilities compounding high-scrutiny GLP-1/incretin products. Facilities in this position should expect that any response addressing only the immediate observations, without a broader assessment of lots released using the same non-worst-case media fills or the same visual inspection system, will be viewed as incomplete. Observations 3 and 4 reinforce this pattern: the written stability program, cited under 21 CFR 211.166(a), lacks a reliable, specific impurity test method for pyridoxine hydrochloride used in the combination tirzepatide product, and cleaning procedures, cited under 21 CFR 211.67(b), lacked swab-based verification after producing testosterone cypionate on a shared line before switching to the tirzepatide combination product — leaving no analytical assurance that cross-contamination residues were adequately removed.

Other 503B and sterile manufacturers should use this 483 to test two things in their own programs: first, whether every bulk drug substance in current compounding use has a documented, current basis under either the 506E shortage list or FDA’s clinical-need list, since that eligibility can change without notice as shortage designations are updated; second, whether media fill protocols have been revisited against actual current production parameters — vial size, fill volume, run speed, and vial count — rather than validated once and left unexamined as production has scaled or diversified.

Decision Relevance

XGene Consulting supports 503B outsourcing facilities and sterile manufacturers with 503B compounding-eligibility assessments, media fill and process validation redesign, visual inspection system qualification, and Warning Letter and 483 remediation. If your facility compounds from bulk substances tied to shifting shortage designations, or your media fill protocols haven’t been revalidated against current production realities, that gap is worth closing before an inspection finds it first.